Seroprevalence of anti-HAV among patients with chronic viral liver disease

Jan 25, 2011

A research team from South Korea investigated the current seroprevalence of hepatitis A virus (HAV) antibodies in patients with chronic viral liver disease in Korea. They found that most Korean patients with chronic liver disease and who are above 40 years of age have already been exposed to HAV.

Hepatitis A virus (HAV) is an epidemiologically important virus with a worldwide distribution and causes acute hepatitis in humans. Acute HAV superinfection causes severe liver disease, acute liver failure and even higher mortality rates in patients with underlying chronic liver disease (CLD). Numerous studies have identified CLD as a risk factor for fulminant and death from acute HAV infection.

A research article to be published on January 14, 2011 in the addresses this question. In this study, the authors investigated the current seroprevalence of HAV (anti-HAV) in patients with chronic viral liver disease in South Korea. They also tried to determine the age-specific seroprevalence in these patients to assess whether vaccination against HAV is necessary in all patients who have underlying viral liver diseases, and to determine the factors that affect IgG anti-HAV seropositivity.

This study showed that the overall prevalence of IgG anti-HAV in Korean patients with chronic viral liver disease was 86.61%, and most patients who are above 40 years of age have already been exposed to HAV. Therefore, vaccination against HAV should be considered, particularly for young anti-HAV-negative patients with chronic liver disease.

Explore further: What is the plague?

More information: Cho HC, Paik SW, Kim YJ, Choi MS, Lee JH, Koh KC, Yoo BC, Son HJ, Kim SW. Seroprevalence of anti-HAV among patients with chronic viral liver disease. World J Gastroenterol 2011; 17(2): 236-241. www.wjgnet.com/1007-9327/full/v17/i2/236.htm

add to favorites email to friend print save as pdf

Related Stories

Anti-HAV antibodies in beta-thalassemia

Apr 30, 2008

Thalassemic patients were found to present a higher prevalence of anti-HAV IgG antibodies than matched healthy subjects from the same geographic area. This finding is difficult to explain, but it may be attributed to the ...

Valuable baseline data of recent hepatitis A in Asian area

Mar 30, 2010

In Korea, there has been a rapid epidemiological shift in hepatitis A virus (HAV) infection as a result of rapid economic development. The adult cases of acute hepatitis A have increased rapidly during the past 10 years due ...

Possible hepatitis C vaccine

Sep 05, 2007

Hepatitis C Virus (HCV) infects up to 500,000 people in the UK alone, many of the infections going undiagnosed. It is the single biggest cause of people requiring a liver transplant in Britain. Now, in a collaborative effort ...

Recommended for you

$1,000 pill now hepatitis C treatment of choice

6 hours ago

(AP)—A $1,000-per-pill drug that insurers are reluctant to pay for has quickly become the treatment of choice for a liver-wasting viral disease that affects more than 3 million Americans.

User comments : 0